Beraprost

This MedLibrary.org supplementary page on Beraprost is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:

Beraprost
Systematic (IUPAC) name
2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-
methyl-1-octen-6-ynyl)-1H-cyclopenta(b)benzofuran-
5-butanoic acid
Identifiers
CAS number 88430-50-6
88475-69-8 (sodium salt)
ATC code B01AC19
PubChem 5282428
Chemical data
Formula C24H30O5 
Mol. mass 398.492 g/mol
Pharmacokinetic data
Bioavailability 50–70%
Metabolism Unknown
Half life 35–40 minutes
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?

Legal status

?

Routes Oral

Beraprost is a synthetic analogue of prostacyclin, under clinical trials for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.

Clinical pharmacology

As an analogue of prostacyclin PGI2, beraprost effects vasodilation, which in turn lowers the blood pressure. Beraprost also inhibits platelet aggregation, though the role this phenomenon may play in relation to pulmonary hypertension has yet to be determined.

Dosage and administration

Beraprost is administered orally as a pill.

Wikipedia content modification information:

  • This page was last modified on 30 May 2008, at 00:34.

Wikipedia Authorship and Review

Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.

Wikipedia Usage Guidelines

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Beraprost".

The URL for this specific entry is:

All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.